Posts Categorized: MS News

MS and Mental Health

MS-UK have produced a new Choices booklet focused on MS and Mental Health. They have a number of ways to view it, and all of the links are below:WebsitePDF

Reading University Study

Reading University are doing a study on psychological intervention for people with MS. Please share this link with your members and encourage them to help inform the study and path of research in this area going forward.  


Coronavirus Public Information: Please follow all guidance being provided by HM Government and NHS regarding the containment of the virus. The news is changing rapidly, please keep up to date with the national and local developments. At the Centre we have provided additional hand sanitisers, tissues, waste bins, and displayed posters reminding people to regularly… Read more »

Coronavirus and MS

Source Multiple Sclerosis International Federation:  The coronavirus and MS – what you need to know The ‘novel coronavirus’ (recently named by the World Health Organization as COVID-19) is a respiratory illness that has not previously been seen in humans. COVID-19 is a strain of coronavirus that was first detected in China in December 2019, and has… Read more »

MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity

Source Multiple Sclerosis News Today:  Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found. The results were published in an article, “Effect of switching from natalizumab to moderate- vs high-efficacy DMT in… Read more »

Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports

Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show. Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast… Read more »

Multiple Sclerosis Drugs Might Not Need To Reach the Brain To Have Clinical Efficacy

Source Technology Networks: Scientists from Trinity College Dublin have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS) and other autoimmune diseases such as psoriasis and rheumatoid arthritis. Their work highlights the significant potential of drugs targeting a specific immune molecule (IL-17) implicated in MS. The scientists,… Read more »

Sanofi MS drug results set stage for extensive late-stage testing

Source With positive results from a mid-stage study in hand, Sanofi is pushing an experimental multiple sclerosis drug into an extensive late-stage research program comprised of four studies scheduled to begin in the middle of this year. More details from the Phase 2b study will be presented at an upcoming medical meeting, according to Sanofi…. Read more »

Gene Variants Linked to High Childhood BMI Point to Higher MS Risk, Study Finds

Source Multiple Sclerosis News Today: Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS) regardless of a person’s vitamin D levels, a study found. The study, “BMI and low vitamin D are causal factors for multiple sclerosis,” was published in the journal Neurology Neuroimmunology & Neuroinflammation. An individual’s risk of developing… Read more »

New Study Asks: When Does MS Begin?

Source National Multiple Sclerosis Society: Researchers from the Harvard T.H. Chan School of Public Health in Boston and collaborators report on a study that examined blood (serum) samples from 60 military personnel who went on to develop multiple sclerosis years later. Compared to samples from a control group, those who eventually developed MS showed higher than… Read more »